• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-SQLE

SQLE Monoclonal Antibody for WB, IF/ICC, Cytometric bead array, Indirect ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain, porc, rat

Applications

WB, IF/ICC, Cytometric bead array, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1C9A2

N° de cat : 67206-1-PBS

Synonymes

1C9A2, EC:1.14.14.17, ERG1, squalene epoxidase, Squalene monooxygenase



Informations sur le produit

67206-1-PBS cible SQLE dans les applications de WB, IF/ICC, Cytometric bead array, Indirect ELISA et montre une réactivité avec des échantillons Humain, porc, rat

Réactivité Humain, porc, rat
Hôte / Isotype Mouse / IgG2a
Clonalité Monoclonal
Type Anticorps
Immunogène SQLE Protéine recombinante Ag3266
Nom complet squalene epoxidase
Masse moléculaire calculée 574 aa, 64 kDa
Poids moléculaire observé 50-64 kDa
Numéro d’acquisition GenBankBC017033
Symbole du gène SQLE
Identification du gène (NCBI) 6713
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

SQLE, also named as ERG1, SE and SM, belongs to the squalene monooxygenase family. It catalyzes the first oxygenation step in cholesterol synthesis, acting on squalene before cyclization into the basic steroid structure. SQLE may serve as a flux-controlling enzyme beyond 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR, considered as rate limiting). It is also posttranslationally regulated by cholesterol-dependent proteasomal degradation. SQLE is subject to feedback regulation via cholesterol-induced degradation, which depends on its lipid-sensing N terminal regulatory domain. Truncation of SQLE occurs during its endoplasmic reticulum-associated degradation and requires the proteasome, which partially degrades the SQLE N-terminus and eliminates cholesterol-sensing elements within this region. The MW of SQLE is about 50-64 kDa. (PMID:21356516, PMID: 28972164)

{{ptg:RelatedPrimaryAntibodies}}